-
Loading metrics
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
- Yoshihito Nagura,
- Kentaro Matsuura,
- Etsuko Iio,
- Koji Fujita,
- Takako Inoue,
- Akihiro Matsumoto,
- Eiji Tanaka,
- Shuhei Nishiguchi,
- Jong-Hon Kang,
- Takeshi Matsui,
- Masaru Enomoto,
- Hiroki Ikeda,
- Tsunamasa Watanabe,
- Chiaki Okuse,
-
Masataka Tsuge,
Roles Resources
Affiliation Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan
⨯ -
Masanori Atsukawa,
Roles Resources
Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
⨯ - Masakuni Tateyama,
-
Hiromi Kataoka,
Roles Resources
Affiliation Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
⨯ - [ ... ],
-
Yasuhito Tanaka
Roles Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing
* E-mail: ytanaka@kumamoto-u.ac.jp
Affiliations Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, Department of Gastroenterology and Hepatology Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan
⨯ - [ view all ]
- [ view less ]
https://orcid.org/0000-0001-7591-8287
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
- Yoshihito Nagura,
- Kentaro Matsuura,
- Etsuko Iio,
- Koji Fujita,
- Takako Inoue,
- Akihiro Matsumoto,
- Eiji Tanaka,
- Shuhei Nishiguchi,
- Jong-Hon Kang,
- Takeshi Matsui
- Published: February 14, 2022
- https://doi.org/10.1371/journal.pone.0263844